BioLight Life Sciences Ltd.
(NOTE: A Public offering: BioLight’s ordinary shares have traded on the Tel Aviv Stock Exchange since December 2005.)
We are an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, DES, and AMD. Our current products and product candidates are designed to address a number of significant unmet medical needs of large and growing patient populations related to these ophthalmic conditions, by reducing patient non-compliance with drug therapy administration, improving efficacy and safety of treatment, offering better diagnosis and optimizing delivery of medications.
|Industry:||SURGICAL & MEDICAL INSTRUMENTS & APPARATUS|
|Address||Kiryat Atidim Building 3, Tel Aviv, 6158101, Israel|
|View Prospectus:||BioLight Life Sciences Ltd.|
|Revenues||$0.4 mil (last 12 months)|
|Net Income||$-7.5 mil (last 12 months)|
|Price range||$4.60 - $6.60|
|Est. $ Volume||$12.0 mil|
|Manager / Joint Managers||Feltl and Company/ Rodman & Renshaw a unit of H.C. Wainwright & Co.|
|Expected To Trade:||3/14/2016|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|